For example, experimental data using the Jurkat T-cell line (ATCC TIB-152) clearly showed that edited SNPs in protein tyrosine phosphatase non-receptor types 2 and 22 (PTPN2/22) were associated with reduced gene expression, resulting in increased cell proliferation and activation and an overactive immune system, suggesting that they may be a potential candidate for future RA gene therapy [80]. This evidence concerns the gene PTPN2 and rheumatoid arthritis.